T. Vincken

Papers on Lattice

Total citations

Topics

h-index

Publication activitypapers/week, last 8 weeks

Frequent co-authors

D. Soliman (2)C. Brezden-Masley (2)S. Sehdev (2)K. El-Ouagari (1)N. Anaya (1)D. Stellato (1)Natalia Sabater-Anaya (1)Sophie Boukouvalas (1)

Papers (2)

Oct 2, 2026

D. Soliman +62w ago

Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2- Early Breast Cancer (EBC): A Canadian Payer Perspective.

Ribociclib plus AI is cost-effective for HR+/HER2- EBC with an ICER of $45,097, below the $50,000 willingness-to-pay threshold versus AI or tamoxifen alone.

D. Soliman, C. Brezden-Masley, S. Sehdev +4

Oct 1, 2026

D. Soliman +52w ago

Societal and Healthcare Costs of Post-IDFS Events Following Adjuvant Ribociclib Plus an Aromatase Inhibitor (AI) Versus AI Alone in Pre- and Postmenopausal Women with Early HR+/HER2- Breast Cancer in Canada

Treatments that reduce disease recurrence and mortality can significantly lower societal costs and alleviate burden on the healthcare system.

D. Soliman, C. Brezden-Masley, S. Sehdev +3

T. Vincken

Publication activitypapers/week, last 8 weeks

Frequent co-authors

Papers (2)

Search

T. Vincken

Publication activitypapers/week, last 8 weeks

Frequent co-authors

Papers (2)